Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Progress in Immunotherapy for Advanced Gastric Cancer

진행성 위암에 대한 면역 요법의 최신 지견

  • Byeong Seok Sohn (Division of Hemato-oncology, Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine)
  • 손병석 (인제대학교 의과대학 상계백병원 혈액종양내과)
  • Received : 2022.05.02
  • Accepted : 2022.05.18
  • Published : 2022.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Immune checkpoint inhibition has been established as a new treatment option for various types of carcinoma, and many clinical trials are being actively conducted as a treatment for advanced or metastatic gastric cancer, either as a monotherapy with an immune checkpoint inhibitor or as a combination therapy with standard chemotherapy. In the CheckMate-649 clinical trial to confirm the efficacy of the combination of nivolumab and chemotherapy (FP) in advanced gastric cancer and gastroesophageal junction cancer, nivolumab group showed improvement in overall survival in programmed death ligand 1-positive cancer patients compared with placebo group. Also, the combination therapy of pembrolizumab, trastuzumab and chemotherapy (FP) in first-line treatment was tested through the KEYNOTE-811 trial. The pembrolizumab group showed 22.7% of improvement in objective response rate compared with placebo group. Accordingly, the combination of nivolumab/pembrolizumab with standard chemotherapy was approved for the first-line treatment. In KEYNOTE-059 trials for patients with progressive disease after at least two lines of chemotherapy, pembrolizumab monotherapy showed improvement in objective response rate and overall survival, and the use of pembrolizumab was approved for the third-line or more treatment. In this article, we review the result of clinical trials related to immune checkpoint inhibitors that have been recently introduced in the treatment of gastric cancer.

Keywords

References

  1. Bang YJ, Cutsem EV, Fuchs CS, et al. KEYNOTE-585: phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer. J Clin Oncol 2018;36(15 Suppl):TPS4136.
  2. Janjigian YY, Cutsem EV, Muro K, et al. MATTER-HORN: efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer- a randomized, double-blind, placebo-controlled, phase 3 study. J Clin Oncol 2021;39(15 Suppl):TPS4151.
  3. Al-Batran SE, Lorenzen S, Thuss-Patience PC, et al. 1494P updated safety data of the DANTE trial: perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma- a randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK. Ann Oncol 2020;31(Suppl 4):S927-S928.
  4. Smyth EC, Knoedler MK, Nilsson M, et al. EORTC 1707 VESTIGE: adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): an open-label randomized controlled phase II study. J Clin Oncol 2020;38(4 Suppl):TPS467.
  5. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
  6. Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603:942-948. https://doi.org/10.1038/s41586-022-04508-4
  7. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:234-247. https://doi.org/10.1016/S1470-2045(21)00692-6
  8. Xu J, Jiang H, Pan Y, et al. LBA53 sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann Oncol 2021;32(Suppl 5):S1331.
  9. Xu R, Arkenau HT, Bang YJ, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. J Clin Oncol 2020;38(4 Suppl):TPS458.
  10. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370
  11. Moehler M, Dvorkin M, Boku N, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. J Clin Oncol 2021;39:966-977.
  12. Janjigian YY, Kawazoe A, Yanez PE, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. J Clin Oncol 2021;39(15 Suppl):4013.
  13. Stein A, Paschold L, Tintelnot J, et al. LBA54- Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): results of the randomized phase II INTEGA trial (AIO STO 0217). Ann Oncol 2021;32(Suppl 5):S1283-S1346.
  14. Shitara K, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123-133. https://doi.org/10.1016/S0140-6736(18)31257-1
  15. Hogner A, Breithaupt K, Stein A, et al. RAP: a phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO). J Clin Oncol 2019;37(15 Suppl):TPS4148.
  16. Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol 2020;21:1066-1076. https://doi.org/10.1016/S1470-2045(20)30326-0
  17. Catenacci DVT, Rosales MK, Chung HC, et al. Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC). J Clin Oncol 2021;39(3 Suppl):TPS264.
  18. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2017;390:2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5
  19. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013. Erratum in: JAMA Oncol 2019;5:579.
  20. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 2018;29:2052-2060.
  21. Yoon HH, Jin Z, Kour O, et al. Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC). J Clin Oncol 2022;40(4 Suppl):344.
  22. Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open 2021;6:100036.
  23. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353-1365. https://doi.org/10.1016/S1470-2045(20)30445-9